Soft tissue sarcoma trials: One size no longer fits all

Journal of Clinical Oncology

Volumn 27, Issue 19, 2009, Pages 3085-3087

  Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEFOROLIMUS; IMATINIB; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PAZOPANIB; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; ANTINEOPLASTIC AGENT;

ADIPOCYTIC SARCOMA; ANTIANGIOGENIC ACTIVITY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG RESPONSE; EDITORIAL; GASTROINTESTINAL STROMAL TUMOR; GENE OVEREXPRESSION; HUMAN; LEIOMYOSARCOMA; METHODOLOGY; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; SARCOMA; SOFT TISSUE TUMOR;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; RESEARCH DESIGN; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 67650309276     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.8180     Document Type: Editorial

References (26)

1. Verweij J, van Oosterom A, Blay JY, et al: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006-2011, 2003
2. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
3. Verweij J, Casali P, Zalcberg J, et al: For the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group and the Australian Gastro-intestinal trials group: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib - A randomised trial. Lancet 364:1127-1134, 2004
4. Debiec-Rychter M, Sciot R, Hogendoorn P, et al: On behalf of the EORTC Soft Tissue and Bone Sarcoma Group, The Italian Sarcoma Group and the Australasia GastroIntestinal Tumor Group: KIT mutations should drive dose selection for imatinib in patients with advanced gastrointestinal stromal tumors - Results of mutation analysis in 377 patients entered into a randomized study. Eur J Cancer 42:1093-1103, 2006
5. Heinrich MC, Owzar K, Corless CL, et al: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26:5360-5367, 2008
6. Van Glabbeke M, Owzar K, Rankin C, et al: Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis based on 1640 patients. J Clin Oncol 25:546s, 2007 (suppl; abstr 10004)
7. Demetri GD, Wang Y, Wehrle E, et al: Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 27:3141-3147, 2009
8. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
9. LeCesne A, Van Glabbeke M, Verweij J, et al: Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial? J Clin Oncol 24:522s, 2006 (suppl; abstr 9510)
10. Judson I, Ma P, Peng B, et al: Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour, a retrospective population pharmacokinetic study over time: EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55:379-386, 2005
11. Chugh R, Wathen JK, Maki RG, et al: Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J Clin Oncol 27:3148-3153, 2009
12. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 17:150-157, 1999
13. Sleijfer S, Ouali M, Van Glabbeke M, et al: Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies. J Clin Oncol 26:555s, 2008 (suppl; abstr 10509)
14. Grosso F, Jones RL, Demetri GD, et al: Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: A retrospective study. Lancet Oncol 8:595-602, 2007
15. Fata F, O'Reilly E, Ilson D, et al: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86:2034-2037, 1999
16. Schlemmer M, Reichardt P, Verweij J, et al: Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 44:2433-2436, 2008
17. Saroha S, Litwin S, Von Mehren M: Retrospective review of treatment for angiosarcomas at Fox Chase Cancer Center over the past 15 years. J Clin Oncol 25:553s, 2007 (suppl; abstr 10034)
18. Nagano T, Tai Y, Higashida Y, et al: Docetaxel monotherapy for angiosarcoma in an elderly patient. Arch Dermatol 143:1602-1603, 2007
19. Maki RG, Wathen JK, Patel SR, et al: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 25:2755-2763, 2007
20. Van Glabbeke M, Verweij J, Judson I, et al: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38:543-549, 2002
21. Verweij J, van Glabbeke M: Translating targets into treatment: Changes in trial methodology and treatment approaches for soft tissue sarcomas. ASCO Educational Book 522-530, 2003
22. Maki RG, D'Adamo DR, Keohan ML, et al: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27:3133-3140, 2009
23. George S, Merriam P, Maki RG, et al: Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27:3154-3160, 2009
24. Sleijfer S, Ray-Coquard I, Papai Z, et al: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol 27:3126-3132, 2009
25. Chawla S, Tolcher AW, Staddon AP: Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue and bone sarcomas: Update of phase II trial. J Clin Oncol 25:563s, 2007 (suppl; abstr 10076)
26. Baker LH, Rowinsky EK, Mendelson D, et al: Randomized phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 26:5583-5588, 2008